MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-08-2022
Albireo Pharma P/E Ratio 2011-2026 | ALBO
Annual P/E Ratio Albireo Pharma
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -15.8 | -6.5 | -4.33 | -6.16 | -11.4 | -2.89 | -0.81 | -2.32 | -2.05 | -1.48 | -2.41 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.81 | -15.8 | -5.1 |
P/E Ratio of other stocks in the Biotechnology industry
| Issuer | P/E Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-0.612 | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-6.57 | $ 3.46 | 1.72 % | $ 1.03 B |  Canada |
 |
Altimmune
ALT
|
-3.61 | $ 3.47 | 3.89 % | $ 306 M |  USA |
 |
Amgen
AMGN
|
25.7 | $ 350.07 | 0.63 % | $ 188 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.7 | $ 19.49 | -0.05 % | $ 911 M | USA |
 |
I-Mab
IMAB
|
-0.236 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
55.7 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
2.49 K | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
-19.2 | $ 220.18 | -0.77 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M | France |
 |
Aurinia Pharmaceuticals
AUPH
|
8.83 | $ 14.83 | 5.78 % | $ 1.99 B | Canada |
 |
Midatech Pharma plc
MTP
|
-14.5 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.57 | - | -1.52 % | $ 24.7 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.92 | $ 1.42 | 3.64 % | $ 362 M | Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
-1.71 | - | - | $ 26.5 M | USA |
 |
Axsome Therapeutics
AXSM
|
-47.3 | $ 154.69 | -1.42 % | $ 7.7 B | USA |
 |
ARCA biopharma
ABIO
|
-5.78 | - | 1052.0 % | $ 415 M | USA |
 |
Aeterna Zentaris
AEZS
|
-4.94 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-0.00095 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-0.0662 | - | -24.86 % | $ 820 K | USA |
 |
Aileron Therapeutics
ALRN
|
-0.608 | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
-4.26 | - | 4.01 % | $ 150 M | Canada |
 |
BioMarin Pharmaceutical
BMRN
|
33.5 | $ 54.66 | 0.97 % | $ 10.5 B | USA |
 |
Benitec Biopharma
BNTC
|
-63.2 | $ 11.25 | 2.46 % | $ 463 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
38.8 | - | - | - |  Russia |
 |
Avenue Therapeutics
ATXI
|
-0.0465 | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-0.583 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-0.463 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-0.0388 | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-0.203 | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
-4.09 | $ 12.74 | - | $ 768 M | USA |
 |
Atreca
BCEL
|
-0.504 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
3.63 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-392 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Coherus BioSciences
CHRS
|
1.35 | $ 1.59 | 4.28 % | $ 186 M | USA |
 |
Calithera Biosciences
CALA
|
-8.34 | - | -10.95 % | $ 876 K | USA |
 |
Cellectis S.A.
CLLS
|
-1.62 | $ 3.38 | 1.05 % | $ 116 M | France |
 |
Cara Therapeutics
CARA
|
-0.457 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-0.0138 | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
-3.96 | - | -74.18 % | $ 955 K | USA |
 |
Checkpoint Therapeutics
CKPT
|
-2.85 | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-0.873 | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-3.48 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-8.58 | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
5.55 | $ 2.13 | 1.9 % | $ 199 M | Israel |
 |
Denali Therapeutics
DNLI
|
-7.19 | $ 20.96 | 3.89 % | $ 3.45 B | USA |
 |
Dyadic International
DYAI
|
-7.08 | $ 0.86 | -8.51 % | $ 24.8 M | USA |
 |
Akero Therapeutics
AKRO
|
-12.9 | - | - | $ 3.67 B | USA |
 |
CorMedix
CRMD
|
0.0028 | $ 6.33 | 1.28 % | $ 456 K | USA |